124 related articles for article (PubMed ID: 36586479)
1. Cancer Antigen 125 Expression Enhances the Gemcitabine/Cisplatin-Resistant Tumor Microenvironment in Bladder Cancer.
Yamashita T; Higashi M; Sugiyama H; Morozumi M; Momose S; Tamaru JI
Am J Pathol; 2023 Mar; 193(3):350-361. PubMed ID: 36586479
[TBL] [Abstract][Full Text] [Related]
2. BMI1 activates P-glycoprotein via transcription repression of
Chen MK; Zhou JH; Wang P; Ye YL; Liu Y; Zhou JW; Chen ZJ; Yang JK; Liao DY; Liang ZJ; Xie X; Zhou QZ; Xue KY; Guo WB; Xia M; Bao JM; Yang C; Duan HF; Wang HY; Huang ZP; Qin ZK; Liu CD
Aging (Albany NY); 2021 Jul; 13(14):18310-18330. PubMed ID: 34270461
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.
Pan J; Li X; Wu W; Xue M; Hou H; Zhai W; Chen W
Cancer Lett; 2016 Nov; 382(1):64-76. PubMed ID: 27591936
[TBL] [Abstract][Full Text] [Related]
4. CD147 and MCT1-potential partners in bladder cancer aggressiveness and cisplatin resistance.
Afonso J; Santos LL; Miranda-Gonçalves V; Morais A; Amaro T; Longatto-Filho A; Baltazar F
Mol Carcinog; 2015 Nov; 54(11):1451-66. PubMed ID: 25263481
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer.
Nordentoft I; Dyrskjøt L; Bødker JS; Wild PJ; Hartmann A; Bertz S; Lehmann J; Orntoft TF; Birkenkamp-Demtroder K
BMC Cancer; 2011 Apr; 11():135. PubMed ID: 21489314
[TBL] [Abstract][Full Text] [Related]
6. A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer.
Goodspeed A; Jean A; Costello JC
Eur Urol; 2019 Feb; 75(2):242-250. PubMed ID: 30414698
[TBL] [Abstract][Full Text] [Related]
7. An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer.
Xylinas E; Hassler MR; Zhuang D; Krzywinski M; Erdem Z; Robinson BD; Elemento O; Clozel T; Shariat SF
Biomolecules; 2016 Sep; 6(3):. PubMed ID: 27598218
[TBL] [Abstract][Full Text] [Related]
8. Impact of immunohistochemistry-based molecular subtype on predicting chemotherapy response and survival in patients with T1 stage bladder cancer after bladder-preserving treatment.
Lu J; Zhang Y; Wu C; Chu C; Liu Z; Cao Y
Jpn J Clin Oncol; 2021 Mar; 51(3):424-433. PubMed ID: 33319245
[TBL] [Abstract][Full Text] [Related]
9. HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer.
Hasanali SL; Morera DS; Racine RR; Hennig M; Ghosh S; Lopez LE; Hupe MC; Escudero DO; Wang J; Zhu H; Sarcan S; Azih I; Zhou M; Jordan AR; Terris MK; Kuczyk MA; Merseburger AS; Lokeshwar VB
Clin Cancer Res; 2021 Aug; 27(15):4410-4421. PubMed ID: 34031055
[TBL] [Abstract][Full Text] [Related]
10. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
[TBL] [Abstract][Full Text] [Related]
11. miR34a/GOLPH3 Axis abrogates Urothelial Bladder Cancer Chemoresistance via Reduced Cancer Stemness.
Zhang Q; Zhuang J; Deng Y; Yang L; Cao W; Chen W; Lin T; Lv X; Yu H; Xue Y; Guo H
Theranostics; 2017; 7(19):4777-4790. PubMed ID: 29187903
[No Abstract] [Full Text] [Related]
12. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
Lyu X; Wang P; Qiao Q; Jiang Y
BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of ribonucleotide reductase subunit M1 protein predicts shorter survival in metastatic bladder cancer patients treated with gemcitabine-containing combination chemotherapy.
Matsumura N; Nakamura Y; Kohjimoto Y; Nishizawa S; Kikkawa K; Iba A; Kodama Y; Hara I
Int J Urol; 2017 Mar; 24(3):230-235. PubMed ID: 28066957
[TBL] [Abstract][Full Text] [Related]
14. No relationship between the amount of DNA damage and the level of hMLH1 and RASSF1A gene expression in bladder cancer cells treated with cisplatin and gemcitabine.
Camargo EA; da Silva GN; Gobette CP; Marcondes JP; Salvadori DM
Asian Pac J Cancer Prev; 2013; 14(10):5941-8. PubMed ID: 24289605
[TBL] [Abstract][Full Text] [Related]
15. Olive Mill Wastewater Inhibits Growth and Proliferation of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro by Down-Regulating the Akt/mTOR-Signaling Pathway.
Rutz J; Maxeiner S; Juengel E; Chun FK; Tsaur I; Blaheta RA
Nutrients; 2022 Jan; 14(2):. PubMed ID: 35057550
[TBL] [Abstract][Full Text] [Related]
16. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
[TBL] [Abstract][Full Text] [Related]
17. S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy.
Kim WT; Kim J; Yan C; Jeong P; Choi SY; Lee OJ; Chae YB; Yun SJ; Lee SC; Kim WJ
Ann Oncol; 2014 May; 25(5):974-9. PubMed ID: 24631944
[TBL] [Abstract][Full Text] [Related]
18. Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity.
Wahlin S; Boman K; Moran B; Nodin B; Gallagher WM; Karnevi E; Jirström K
BMC Cancer; 2022 Feb; 22(1):131. PubMed ID: 35109796
[TBL] [Abstract][Full Text] [Related]
19. Biased Expression of the FOXP3Δ3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance.
Zhang H; Prado K; Zhang KX; Peek EM; Lee J; Wang X; Huang J; Li G; Pellegrini M; Chin AI
Clin Cancer Res; 2016 Nov; 22(21):5349-5361. PubMed ID: 27189164
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of cisplatin resistance in bladder cancer.
Drayton RM; Catto JW
Expert Rev Anticancer Ther; 2012 Feb; 12(2):271-81. PubMed ID: 22316374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
